The biopharmaceutical company Arbutus Biopharma Corporation (ABUS), a subsidiary of Roivant Sciences Ltd. (ROIV), is currently actively evaluating a capital return plan.
Show original
The plan aims to return capital to the company's shareholders in the third quarter of the 2026 calendar year.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
US stocks outperform globally, with energy independence and technological resilience as key factors
Chaincatcher•2026/03/06 10:54
JPMorgan: Oracle Stock Price Is Overly Discounted
BlockBeats•2026/03/06 10:54
Capital Economics: Risks Facing the Indian Economy Go Beyond Oil
金十•2026/03/06 10:53
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$70,572.51
-3.92%
Ethereum
ETH
$2,066.74
-4.26%
Tether USDt
USDT
$1
-0.02%
BNB
BNB
$640.35
-3.59%
XRP
XRP
$1.4
-3.14%
USDC
USDC
$1.0000
-0.00%
Solana
SOL
$87.81
-5.31%
TRON
TRX
$0.2869
+0.77%
Dogecoin
DOGE
$0.09368
-4.02%
Cardano
ADA
$0.2681
-3.18%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now